{"organizations": [], "uuid": "87dbda412529b15c5851498115cc01f15c4cdace", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180306.html", "section_title": "Archive News &amp; Video for Tuesday, 06 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-bristol-myers-squibbs-opdivo-now-t/brief-bristol-myers-squibbs-opdivo-now-the-first-and-only-fda-approved-pd-1-inhibitor-to-offer-every-four-week-dosing-idUSFWN1QO0EA", "country": "US", "domain_rank": 408, "title": "BRIEF-Bristol-Myers Squibb's Opdivo Now The First And Only FDA-Approved PD-1 Inhibitor To Offer Every Four-Week Dosing", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-03-06T20:09:00.000+02:00", "replies_count": 0, "uuid": "87dbda412529b15c5851498115cc01f15c4cdace"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-bristol-myers-squibbs-opdivo-now-t/brief-bristol-myers-squibbs-opdivo-now-the-first-and-only-fda-approved-pd-1-inhibitor-to-offer-every-four-week-dosing-idUSFWN1QO0EA", "ord_in_thread": 0, "title": "BRIEF-Bristol-Myers Squibb's Opdivo Now The First And Only FDA-Approved PD-1 Inhibitor To Offer Every Four-Week Dosing", "locations": [], "entities": {"persons": [{"name": "opdivo", "sentiment": "none"}], "locations": [], "organizations": [{"name": "squibb co", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "brief-bristol-myers squibb", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 6 (Reuters) - Bristol-Myers Squibb Co:\n* BRISTOL-MYERS SQUIBB’S OPDIVO® (NIVOLUMAB) NOW THE FIRST AND ONLY FDA-APPROVED PD-1 INHIBITOR TO OFFER EVERY FOUR-WEEK DOSING\n* BRISTOL-MYERS SQUIBB - ‍ OPDIVO ALSO WAS APPROVED FOR A SHORTER 30-MINUTE INFUSION ACROSS ALL APPROVED INDICATIONS​\n* BRISTOL-MYERS SQUIBB - FDA APPROVES OPDIVO LABEL UPDATE OFFERING FLEXIBLE FLAT-DOSING OPTIONS EVERY TWO WEEKS (240 MG) OR EVERY FOUR WEEKS (480 MG)​\n* BRISTOL-MYERS SQUIBB CO - ‍DOSING SCHEDULE UPDATES FOR AN ADDITIONAL APPROVED INDICATION FOR OPDIVO MAY BE SUBMITTED TO FDA IN FUTURE FOR OPDIVO​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-06T20:09:00.000+02:00", "crawled": "2018-03-07T19:54:14.038+02:00", "highlightTitle": ""}